[{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Advicenne","sponsor":"FrostPharma AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ FrostPharma AB","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ FrostPharma AB"},{"orgOrder":0,"company":"Advicenne","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Potassium Citrate","moa":"Calcium","graph1":"Nephrology","graph2":"Approved","graph3":"Advicenne","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Advicenne \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Advicenne \/ Not Applicable"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Potassium Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-Release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite Bioscience \/ Advicenne"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"Advicenne","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"NETHERLANDS","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Potassium Citrate","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Prolonged-release Granule","sponsorNew":"Avanzanite Bioscience \/ Advicenne","highestDevelopmentStatusID":"12","companyTruncated":"Avanzanite Bioscience \/ Advicenne"}]

Find Clinical Drug Pipeline Developments & Deals for Potassium Citrate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Under the partnership, Avanzanite gains commercialization and distribution rights into three additional European countries, for Sibnayal (potassium citrate and potassium bicarbonate), the first approved medicinal product in Europe for distal Renal Tubula...

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Undisclosed

October 18, 2023

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : Advicenne

Deal Size : Undisclosed

Deal Type : Partnership

blank

02

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Sibnayal (potassium citrate) is a medicine used to treat patients from the age of one year with distal renal tubular acidosis (dRTA), a disease in which the kidneys do not remove acid through the urine well enough.

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Undisclosed

February 28, 2023

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : Advicenne

Deal Size : Undisclosed

Deal Type : Agreement

blank

03

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Under the terms of the agreement, FrostPharma will receive exclusive marketing rights to Sibnayal™ for the treatment of dRTA. Advicenne will receive a transfer price for the sale of its product and royalties for an amount significantly higher than 50% ...

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Undisclosed

January 04, 2022

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : FrostPharma AB

Deal Size : Undisclosed

Deal Type : Agreement

blank

04

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Sibnayal™ is a multi-particulate formulation in 2mm granules, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients.

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Not Applicable

July 02, 2021

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : Advicenne’s lead product, ADV7103, is developed as a multi-particulate formulation in 2mm microtablets, a novel pioneering delivery technology created by Advicenne that contains two active pharmaceutical ingredients to ease its administration.

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Not Applicable

May 17, 2021

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

06

ICHH-25
Not Confirmed
ICHH-25
Not Confirmed

Details : ADV7103/Sibnayal (potassium citrate) becomes the first and only label-approved drug for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older.

Product Name : Sibnayal

Product Type : Small molecule

Upfront Cash : Not Applicable

May 03, 2021

Lead Product(s) : Potassium Citrate,Potassium hydrogen carbonate

Therapeutic Area : Nephrology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank